Clinical director of the Irish health technology assessment (HTA) body National Centre for Pharmacoeconomics (NCP), Michael Barry, MB, FRCPI, PhD, recently said in an interview with Irish media that the lack of uptake of biosimilars in Ireland is “an issue that should be tackled,” and he proposed approaches to do just that.
Clinical director of the Irish health technology assessment (HTA) body National Centre for Pharmacoeconomics (NCP), Michael Barry, MB, FRCPI, PhD, recently said in an interview with Irish media that the lack of uptake of biosimilars in Ireland is “an issue that should be tackled.”
He went on to explain that “The [Health Service Executive, HSE] needs to take this one seriously and to have a good quality team producing a policy and also implementing it and, in addition, empowering excellent pharmacy units in our hospitals.”
Click here to read more about biosimilars in Ireland.
Barry explained that, among his colleagues, there is an appreciation that safety and efficacy of drug products is important, but prescribers should not overlook the cost issue of medicines. He also had recommendations for how to approach the issue, beginning with the creation of a policy that states that, unless there are extenuating circumstances, a patient starting treatment on a biologic should begin with a biosimilar.
“Then you’ve got to put in the structures to enable this to happen at a hospital level. We have spent the last 5 years concentrating on community expenditure because that is where most of it takes place, but we need to get to grips with hospital prescribing,” he said.
Though the United States has also seen a similar lack of biosimilar uptake, the nations differ in terms of their challenges and approaches to addressing them. While CMS recently announced that it would allow Medicare Advantage plans to use step therapy that could involve starting patients on biosimilars, that policy initiative does not extend to commercial plans (and experience with step therapy used in commercial plans to date has shown that biosimilars are not typically used first). Neither has the United States made special initiatives to address hospital- versus community-based biosimilar prescribing.
Furthermore, in the United States, there are just 4 biosimilars on the market, compared with Ireland’s 11 reimbursable biosimilars (as of the date of Ireland’s Minister for Health publication of a consultation paper on developing a national policy on biosimilars).
The slow biosimilar uptake in both the United States and Ireland has cost each country’s respective health system greatly, however. Last month, Medicines for Ireland released a report stating that Ireland’s policies are keeping the nation from benefitting from €25m (approximately $29 million) in annual savings to its national health system. Similarly, in the United States, biosimilars had been projected to save nearly $54 billion from 2017 to 2026, but the actual realized savings thus far are only “a fraction of even the most conservative initial estimates,” said FDA Commissioner Scott Gottlieb, MD, in a recent statement.
What remains the same throughout any market looking to increase the use of biosimilars is that it is not a feat that can be accomplished by a single organization or government entity. During the announcement of the FDA’s Biosimilar Action Plan, Gottlieb stated that achieving the cost savings projected for biosimilars will require actions from both the public and private sector. Barry is of a similar mindset, explaining that the benefits of biosimilars are obvious, but “resources are needed to put the strategy in place.”
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.